Figure_8.tif (586.15 kB)
Patients' outcome according to KRAS-BRAF mutations status and AREG or EREG mRNA expression.
figure
posted on 2013-02-20, 21:14 authored by Zacharenia Saridaki, Maria Tzardi, Chara Papadaki, Maria Sfakianaki, Fraga Pega, Aristea Kalikaki, Eleftheria Tsakalaki, Maria Trypaki, Ippokratis Messaritakis, Efstathios Stathopoulos, Dimitris Mavroudis, Vassilis Georgoulias, John SouglakosPanel A: Time to Tumor Progression (TTP) according to KRAS-BRAF mutations status and AREG mRNA expression. Panel B: Median Overall Survival (OS) according to KRAS-BRAF mutations status and AREG mRNA expression. Panel C: Time to Tumor Progression (TTP) according to KRAS-BRAF mutations status and EREG mRNA. Panel D Median Overall Survival (OS) according to KRAS-BRAF mutations status and EREG mRNA.
